Jing Watnick

Company: Vigeo Therapeutics

Job title: Founder & Chief Operating Officer

Seminars:

Leveraging Immune Checkpoint Inhibitors to Target Multiple Tumor Microenvironment Cell Population 1:30 pm

Novel biological activity stimulates thrombospondin-1 expression to target myeloid and inflammatory cells in the TME via CD36 and CD47 Understand the influence of the TME and peripheral immune cells in GBM IO treatment Discuss promising biomarkers for responses to immune checkpoint inhibitorsRead more

day: Conference Day 2